As a pharmacoeconomist and epidemiologist, I aim to identify high-value drugs, vaccines, and diagnostics in development. By creating mathematical models of infectious diseases, we can conduct comparative-effectiveness research to prioritize clinical research and develop strategies for pharmaceutical portfolios.
- Microsimulation model of dynamic decision-making in chronic myeloid leukemia using biomarker trajectories for early treatment switching (University of Washington [UW], PhRMA Foundation)
- Economic impact of comparative-effectiveness research studies in the United States (PCORI)
- Incentivizing health-promoting behaviors: the cost-effectiveness of financial incentives for viral suppression in New York and Washington, DC (HPTN 065)
- Dynamic transmission model of potential competition and substitution of pre-exposure prophylaxis with availability of HIV vaccines among men who have sex with men in Seattle, WA (UW, Fred Hutch)
- Costs and cost-effectiveness of intervention diagnosing acute HIV infections among high-risk men in Lima, Peru (SABES Study)
- Potential HIV vaccine effectiveness and technical efficiency in South Africa using a dynamic transmission model (HVTN 702)
- Target product profile and economics for point-of-care diagnostics for HIV, chlamydia, and influenza
- Methods for censoring costs and outcomes at the time horizon in dynamic transmission microsimulation models (Institute for Disease Modeling)
Here are some awards we have received for this research.